Stock Analysis on Net
Stock Analysis on Net

Gilead Sciences Inc. (NASDAQ:GILD)

Common-Size Income Statement 

Gilead Sciences Inc., common-size consolidated income statement

Microsoft Excel
12 months ended: Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Product sales 100.00 100.00 100.00 100.00 100.00
Cost of goods sold -21.85 -24.13 -20.97 -24.44 -18.77
Gross profit on product sales 78.15% 75.87% 79.03% 75.56% 81.23%
Royalty, contract and other revenues 0.50 0.68 1.11 1.10 1.37
Research and development expenses -20.65 -21.23 -18.45 -19.86 -20.69
Acquired in-process research and development expenses -16.30 -4.29 -3.50 -0.66 -24.04
In-process research and development impairment -14.61 -0.19 -10.01 0.00 0.00
Selling, general and administrative expenses -21.29 -22.61 -21.03 -19.42 -21.15
Operating income 5.81% 28.24% 27.17% 36.72% 16.72%
Interest expense -3.41 -3.50 -3.47 -3.71 -4.04
Loss from equity securities, net -0.96 -0.62 -2.43 0.00 0.00
Interest income 0.98 1.40 0.39 0.00 0.00
Other, net -0.01 -0.04 -0.11 -2.37 -5.82
Other income (expense), net 0.02% 0.74% -2.15% -2.37% -5.82%
Income before income taxes 2.41% 25.47% 21.55% 30.65% 6.85%
Income tax expense -0.73 -4.63 -4.63 -7.69 -6.49
Net income 1.68% 20.84% 16.92% 22.96% 0.37%
Net loss attributable to noncontrolling interest 0.00 0.19 0.10 0.09 0.14
Net income attributable to Gilead 1.68% 21.03% 17.02% 23.05% 0.51%

Based on: 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Gilead Sciences Inc. operating income as a percentage of product sales increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Income before income taxes Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Gilead Sciences Inc. income before income taxes as a percentage of product sales increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.
Net income attributable to Gilead The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Gilead Sciences Inc. net income attributable to Gilead as a percentage of product sales increased from 2022 to 2023 but then decreased significantly from 2023 to 2024.